Tag: LigaChem Biosciences

WuXi XDC Cayman, a global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on antibody-drug conjugates (ADCs), confirmed the signing of an expanded Memorandum of Understanding (MOU) with LigaChem Biosciences for the ongoing development of novel ADC therapies targeting cancer and other serious diseases. This new agreement broadens the scope of the ongoing collaboration, further accelerating the development of next generation innovative ADC therapies.

South Korea-based DAAN Biotherapeutics has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).